Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Talzenna
Pharma
Pfizer’s Talzenna combo moves up treatment line with FDA nod
Pfizer’s Talzenna moves into an earlier prostate cancer treatment setting after an FDA nod backed by a 52% reduction in progression or death.
Donavyn Coffey
Oct 26, 2026 3:27pm
ASCO: Pfizer one-ups J&J in prostate cancer
May 30, 2026 8:00am
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
Mar 19, 2026 6:45am
FDA advisors unanimously reject Pfizer's Talzenna expansion bid
May 22, 2025 10:20am
J&J, Pfizer and Roche face FDA questions over data applicability
May 16, 2025 3:52pm
FDA to host first oncology adcomm meeting under Makary
May 8, 2025 11:35am
